About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.
Dyadic makes financial disclosures through the OTC Disclosure and News Service which offers free information on the OTC Markets website (www.otcmarkets.com) concerning companies traded on the OTC Markets. Investors can access and download Dyadic's financial reports and other announcements that Dyadic makes through the OTC Markets website. Dyadic will also continue providing updates through regular press releases as appropriate.
Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months Ended March 31,20112010Revenue: (Unaudited) (Unaudited) Product Related Revenue, Net
1,879,145License Fee Revenue-32,000Research and Development Revenue491,30988,235Total Revenue2,296,5171,999,380Cost of Goods Sold1,528,2271,605,324Gross Profit768,290394,055Expenses:General and Administrative1,684,6901,359,667Sales and Marketing 267,734226,733Research and Development 304,003286,042Foreign Currency Exchange Losses (Gains), Net(94,034)33,294Total Expenses2,162,3
|SOURCE Dyadic International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved